

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re the Application of:

YUSUKE SAKAI, ET AL.

Application No.: 10/573,191

Filed: March 21, 2006

For: **Pharmaceutical Composition Containing
Prostaglandin**

Art Group: 1614

Examiner: Unknown

Confirmation No.: 4940

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure, enclosed is a copy of an Information Disclosure Statement by Applicant (form PTO/SB/08), which is being submitted before the mailing of a first Office Action. It is respectfully requested that the cited references be considered and that the enclosed copy of PTO/SB/08 be initialed by the Examiner to indicate such consideration and a copy thereof returned to applicant(s).

The submission of this Information Disclosure Statement is not to be construed as a representation that a search has been made in the subject application and is not to be construed as an admission that the information cited in this statement is material to patentability.

Applicant has concurrently submitted an electronic Information Disclosure Statement (IDS) for the above-referenced patent application. In the concurrently filed electronic IDS submission, it was requested that any requisite fees be debited from Deposit Account 02-2666. Applicant respectfully requests that only one fee be debited for these concurrently filed IDS submissions if such fees are required.

Respectfully submitted,

BLAKELY, SOKOLOFF, TAYLOR & ZAFMAN LLP

Date: 4/15/08



William Thomas Babbitt, Reg. No. 39,591

1279 Oakmead Parkway
Sunnyvale, CA 94085-4040
Telephone: (310) 207-3800

I hereby certify that this correspondence is being submitted electronically via EFS Web on the date shown below.

Nedy Calderon
Nedy Calderon

4/15/08

Date